Art Unit 1619
Group 1610Pharmaceutical and Agricultural Compositions
- Active examiners
- 20
- Average office actions per grant
- 2.96
Grant ratio
- Art Unit 1619
- 33.2%
- Group 1610
- 43.3%
Active examiners
| Tigabu Kassa | 31.9% | 3.40 | August 2026 |
|---|---|---|---|
| Sarah Al-Awadi | 33.3% | 3.09 | August 2026 |
| Ivan Greene | 15.9% | 3.36 | August 2026 |
| Thurman Wheeler | 41.7% | 3.21 | August 2026 |
| Sarah Chickos | 36.2% | 3.15 | August 2026 |
| Garen Gotfredson | 34.5% | 3.28 | August 2026 |
| Nicole Plourde Babson | 38.3% | 3.04 | August 2026 |
| Alissa Prosser | 14.2% | 3.28 | August 2026 |
| Daniel F. Coughlin | 34.5% | 3.32 | August 2026 |
| Lori K Mattison | 12.5% | 3.42 | August 2026 |
| John P Nguyen | 39.2% | 2.71 | August 2026 |
| Edwin C Mitchell | 16.4% | 2.44 | August 2026 |
| Shanon A. Foley | 46.1% | 1.68 | August 2026 |
| Sean J. Steinke | 0.0% | N/A | August 2026 |
| Kaeleigh Elizabeth Olsen | 3.5% | 1.00 | August 2026 |
| David J. Blanchard | 18.6% | 1.93 | June 2026 |
| Brian Gulledge | 0.0% | 2.60 | August 2026 |
| Jennifer A Berrios | 10.0% | 2.73 | August 2026 |
| Matthew Ryan Burke | 0.0% | N/A | August 2026 |
| Liliana Cerullo | 0.0% | 1.00 | July 2026 |
Examiner distribution
- Median grant ratio
- 18.6%
- Middle 50% of grant ratios
- 11.3%–35.3%
- Median office actions / grant
- 3.09
- Middle 50% of office actions / grant
- 2.60–3.28
Active examiners with at least 20 applications.
Other associated examiners
Examiners without recent activity.
| Jyothsna Venkat | 56.6% | 2.38 | August 2023 Appears inactive |
|---|---|---|---|
| Suzanne Ziska | 56.3% | 2.75 | December 2023 Appears inactive |
| Devang Thakor, Ph.D | 34.4% | 2.95 | August 2020 Appears inactive |
| Christopher R. Lea | 22.6% | 2.24 | August 2013 Appears inactive |
| Donna Jagoe | 17.9% | 2.27 | August 2010 Appears inactive |
| Tracey Simmons Willis | 5.9% | 2.50 | November 2009 Appears inactive |
| Raymond P. Yeager | 0.0% | 1.00 | November 2009 Appears inactive |
| Tracey Simmons Willis | 0.0% | N/A | October 2009 Appears inactive |
Based on available public USPTO records; may be incomplete.